IDP-122 Lotion

DRUG4 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Plaque PsoriasisPsoriasis

Phase 2

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

CompletedNCT02785185

Bausch Health Americas, Inc.Psoriasis

Start: 2016-06-30End: 2017-01-31Updated: 2020-08-27

Phase 3

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

CompletedNCT02514577

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2015-11-07End: 2017-05-01Updated: 2020-01-27

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

CompletedNCT02515097

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2015-11-05End: 2017-03-15Updated: 2020-01-27

Phase 4

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

RecruitingNCT03987763

Bausch Health Americas, Inc.Psoriasis

Start: 2019-10-22End: 2026-06-30Target: 45Updated: 2025-08-27

Related Papers

Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants.

2021-03-012 citations

A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis

Journal of Dermatological Treatment2018-09-127 citations